AG 1343 DOSE FINDING STUDY IN HIV+ PATIENTS

这项研究的目标是： 1.评估不同剂量和/或剂量方案的安全性 AG1343给予食物和8-12盎司水，为期4周 HIV阳性患者的单一疗法。 2.评估不同剂量和/或剂量方案的临床活性 使用HIV病毒学和免疫学标志物的AG1343 进展，即定量血浆HIV RNA滴度，绝对CD4/CD8 计数和百分比，以及p24抗原水平，以确定最佳剂量 更大规模II期对照试验的方案。 3.测定不同剂量/剂量下AG1343的药代动力学 HIV阳性患者的治疗方案。

The goals of this study are: 1. To evaluate the safety of different doses and/or dose regimens of AG1343 administered with food and 8-12 ounces of water for 4 weeks of monotherapy in HIV positive patients. 2. To assess clinical activity of different doses and/or dose regimens of AG1343 using virologic and immunologic markers of HIV disease progressions, i.e., quantitative plasma HIV RNA titer, absolute CD4/CD8 count and percentage, and p24 antigen level to establish optimum dosing regimen for larger phase II controlled trials. 3. To determine the pharmacokinetics of AG1343 at different doses/dose regimens in HIV positive patients.